MedTrace Logo

ERP N1 as a Treatment Predictor of Generalized Anxiety Disorder

NCT00613067 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2010-06-30

No results posted yet for this study

Summary

Amplitude changes of the N1 and the N1/P2 ERP component in response to different tone intensities have been suggested as a correlative of central serotonergic activity. A strong loudness dependence amplitude increase (strong intensity dependence) reflects low serotonergic neurotransmission and vice versa. Many researchers assumed that the brain serotonergic activity could influence treatment response of highly selective serotonin reuptake inhibitors in depression and anxiety disorders. There are a couple of studies reporting associations of N1 amplitude intensity dependence with response to Citalopram (positive correlation) and Reboxetine (negative correlation) treatment in major depressive disorder patients. But so far there have been no reports about associations between ERP N1 and antidepressant response in GAD patients.

So, it would be very interesting to explore the correlations between ERP N1 amplitude change and the Escitalopram treatment responsiveness in GAD patients.

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

escitalopram

* Start with escitalopram 10mg * According to patient's symptoms, stay on 10mg or increase up to 20mg * Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages * Length of washout period will be at least 2 weeks for any psychotropic drugs

Sponsors & Collaborators

  • Inje University

    lead OTHER

Principal Investigators

  • Seung-Hwan Lee, MD, PhD · Psychiatry department, Inje Univ. Ilsanpaik Hospital

  • Young-Min Park, MD, PhD · Psychiatry department, Inje Univ. Ilsanpaik Hospital

  • Sung-Man Bae, PhD · Psychiatry department, Inje Univ. Ilsanpaik Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2010-04-30
Completion
2010-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00613067 on ClinicalTrials.gov